Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes

	Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes
	Chen, Jihui 1,2,3; Cui, Wentong 4; Zhang, Quanbin 5; Jia, Yingli 1,2; Sun, Yi 1,2; Weng, Lin 1,2; Luo, Dali 4; Zhou, Hong 1,2; Yang, Baoxue 1,2
刊名	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
	2015
卷号	7 期号:9 页码:1553-1563
关键词	Fucoidan diabetic nephropathy epithelialto-mesenchymal transition transforming growth factor-beta 1 extracellular matrix tubulointerstitial fibrosis
英文摘要	Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes and may lead to end-stage renal disease (ESRD) and chronic renal failure. The aim of this study was to determine whether low-molecular-weight fucoidan (LMWF) can reduce harmful transforming growth factor-beta (TGF-beta)-mediated renal fibrosis in DN using in vitro and in vivo experimental models. The experimental results showed that LMWF significantly reversed TGF-beta 1-induced epithelial-mesenchymal transition and dose-dependently inhibited accumulation of extracellular matrix proteins, including connective tissue growth factor and fibronectin. It was found that LMWF significantly reduced blood urea nitrogen and blood creatinine in both type 1 and type 2 diabetic rat models. H&E, PAS and Masson's trichrome staining of kidney tissue showed LMWF significantly reduced renal interstitial fibrosis. Treatment with LMWF significantly increased E-cadherin expression and reduced alpha-SMA, CTGF and fibronectin expression in both type 1 and type 2 diabetic models. LMWF also decreased the phosphorylation of Akt, ERK1/2, p38 and Smad3 in vitro and in vivo. These data suggest that LMWF may protect kidney from dysfunction and fibrogenesis by inhibiting TGF-beta pathway and have the potential benefit to slow down the progression of DN.
收录类别	SCI
语种	英语
WOS记录号	WOS:000364771500007
内容类型	期刊论文
源URL	[http://ir.qdio.ac.cn/handle/337002/82294]
专题	海洋研究所_海洋生物技术研发中心
作者单位	1.Peking Univ, Sch Basic Med Sci, Minist Educ, State Key Lab Nat & Biomimet Drugs,Key Lab Mol Ca, Beijing 100191, Peoples R China 2.Peking Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing 100191, Peoples R China 3.Shanghai Jiao Tong Univ, Sch Med, Dept Pharm, Xin Hua Hosp, Shanghai 200092, Peoples R China 4.Capital Med Univ, Dept Pharmacol, Beijing 100069, Peoples R China 5.Chinese Acad Sci, Inst Oceanol, Qingdao 266071, Peoples R China
推荐引用方式 GB/T 7714	Chen, Jihui,Cui, Wentong,Zhang, Quanbin,et al. Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes[J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH,2015,7(9):1553-1563.
APA	Chen, Jihui.,Cui, Wentong.,Zhang, Quanbin.,Jia, Yingli.,Sun, Yi.,...&Yang, Baoxue.(2015).Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes.AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH,7(9),1553-1563.
MLA	Chen, Jihui,et al."Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes".AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH 7.9(2015):1553-1563.